Related Experiment Video

Updated: Oct 9, 2026

Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
08:01

Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System

Published on: June 11, 2020

Na(+)/H(+) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats

K Kusumoto1, J V Haist, M Karmazyn

  • 1Department of Pharmacology and Toxicology, The University of Western Ontario, London, Ontario, Canada N6A 5C1.

American Journal of Physiology. Heart and Circulatory Physiology
|February 13, 2001
PubMed

Insights

Sodium/hydrogen exchange inhibition (NHE-1) with cariporide reduced heart failure progression and hypertrophy in rats post-myocardial infarction. This NHE-1 inhibition preserved cardiac function and reduced left ventricular dilation, suggesting a key role in heart failure development.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Coronary artery ligation (CAL) in rats leads to cardiac hypertrophy and heart failure.
  • Sodium/hydrogen exchange (NHE-1) plays a role in cardiac cell function and survival.

Purpose of the Study:

  • To investigate the effect of NHE-1 inhibition on cardiac hypertrophy and heart failure following myocardial infarction in a rat model.
  • To evaluate the therapeutic potential of the NHE-1 inhibitor cariporide in mitigating post-infarction cardiac dysfunction.

Main Methods:

  • Rats underwent coronary artery ligation (CAL) or sham surgery.
  • Animals received either a control diet or a diet containing the NHE-1 inhibitor cariporide for 13-15 weeks.
  • Hearts were analyzed based on infarct size (small ≤30% LV, large >30% LV) and assessed for functional parameters and hypertrophy.

Main Results:

  • CAL significantly reduced left ventricular function (LV +dP/dt), an effect attenuated by cariporide.
  • Cariporide significantly reduced the marked increase in LV end-diastolic pressure and LV dilation observed in rats with large infarcts.
  • NHE-1 inhibition with cariporide reduced cardiac hypertrophy and preserved myocyte shortening, without affecting infarct size, blood pressure, or dobutamine response.

Conclusions:

  • Sodium/hydrogen exchange (NHE-1) plays a critical role in the progression of heart failure after myocardial infarction.
  • Inhibition of NHE-1 with cariporide demonstrates a protective effect against cardiac remodeling and dysfunction post-infarction in rats.
  • Targeting NHE-1 may represent a viable therapeutic strategy for managing heart failure following myocardial infarction.

More Related Videos

Acute Myocardial Infarction in Rats07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...